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BACKGROUND: Preterm delivery remains the leading cause of peri- used in discovery and verification. Strict blinding and independent sta-
natal mortality. Risk factors and biomarkers have traditionally failed to
identify the majority of preterm deliveries.
OBJECTIVE: To develop and validate a mass spectrometryebased
serum test to predict spontaneous preterm delivery in asymptomatic
pregnant women.
STUDY DESIGN: A total of 5501 pregnant women were enrolled be-
tween 170/7 and 286/7 weeks gestational age in the prospective Proteomic
Assessment of Preterm Risk study at 11 sites in the United States between
2011 and 2013. Maternal blood was collected at enrollment and out-
comes collected following delivery. Maternal serum was processed by a
proteomic workflow, and proteins were quantified by multiple reaction
monitoring mass spectrometry. The discovery and verification process
identified 2 serum proteins, insulin-like growth factorebinding protein 4
(IBP4) and sex hormoneebinding globulin (SHBG), as predictors of
spontaneous preterm delivery. We evaluated a predictor using the log ratio
of the measures of IBP4 and SHBG (IBP4/SHBG) in a clinical validation
study to classify spontaneous preterm delivery cases (<370/7 weeks
gestational age) in a nested case-control cohort different from subjectsCite this article as: Saade GR, Boggess KA, Sullivan SA,
et al. Development and validation of a spontaneous
preterm delivery predictor in asymptomatic women. Am J
Obstet Gynecol 2016;214:633.e1-24.
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RESULTS: The predictor had an area under the receiver operating
characteristic curve value of 0.75 and sensitivity and specificity of 0.75
and 0.74, respectively. The IBP4/SHBG predictor at this sensitivity and
specificity had an odds ratio of 5.04 for spontaneous preterm delivery.
Accuracy of the IBP4/SHBG predictor increased using earlier case-vs-
control gestational age cutoffs (eg, <350/7 vs 350/7 weeks gestational
age). Importantly, higher-risk subjects defined by the IBP4/SHBG predictor
score generally gave birth earlier than lower-risk subjects.
CONCLUSION: A serum-based molecular predictor identifies
asymptomatic pregnant women at risk of spontaneous preterm delivery,
which may provide utility in identifying women at risk at an early stage of
pregnancy to allow for clinical intervention. This early detection would
guide enhanced levels of care and accelerate development of clinical
strategies to prevent preterm delivery.
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IBP4, SHBGreterm birth (PTB), deﬁned as de-P livery before 37 weeks of gestation,
affects 15 million infants born each year,
varying from approximately 5% to 18%
of all births across different geographies
worldwide.1 In the United States, it is the
leading cause of neonatal death and the
second-leading cause of death in chil-
dren before age 5 years. PTB is also a
major source of long-term health con-
sequences, including chronic lung dis-
ease, hearing and visual impairments,
and neurodevelopmental disabilities,such as cerebral palsy. The health-
economic impact of PTB in 2005 in the
United States was estimated to be above
$26 billion,2 and costs continue to rise in
most countries.3,4
Prior history of spontaneous preterm
delivery (sPTD) is currently the single
strongest predictor of subsequent PTD.
After 1 prior sPTD, the probability of a
second PTD is 30e50%.5-7 Other
maternal risk factors include black race,
low maternal body mass index (BMI),
and short cervical length.8,9 Amniotic
ﬂuid, cervicovaginal ﬂuid, and serum
biomarker studies to predict sPTD sug-
gest that multiple molecular pathways
are aberrant in women who ultimately
deliver preterm.10-13
Despite intense research to identify at-
risk women, PTD prediction algorithms
based solely on clinical and demographicMAY 2016 Amerifactors or using measured serum or
vaginal biomarkers have not resulted in
clinically useful tests.14-17 More accurate
methods to identify women at risk dur-
ing their ﬁrst pregnancy and sufﬁciently
early in gestation are needed to allow for
clinical intervention. The purpose of the
project was to develop a proteomic
signature proﬁle for the prediction of
sPTD and to validate this proﬁle in a
separate independent sample of new
subjects.
Materials and Methods
Subjects
The Proteomic Assessment of Preterm
Risk (PAPR) study was conducted under
a standardized protocol at 11 Institutional
Review Board (IRB)-approved sites
across the United States (Clinicaltrials.
gov identiﬁer: NCT01371019). Subjects
were enrolled between 170/7 and 286/7
weeks gestational age (GA). Dating wascan Journal of Obstetrics& Gynecology 633.e1
Original Research OBSTETRICS ajog.orgestablished using a predeﬁned protocol of
menstrual dating conﬁrmed by early ul-
trasound biometry, or ultrasound alone,
to provide the best clinically estimated
GA. BMI was derived from height and
prepregnancy self-reported weight. Preg-
nancies with multiple gestations or with
known or suspected major fetal anoma-
lies were excluded. Pertinent information
regarding subject demographic charac-
teristics, past medical and pregnancy
history, current pregnancy history, and
concurrent medications was collected
and entered into an electronic case report
form. Following delivery, data were
collected for maternal and infant out-
comes and complications. All deliveries
were classiﬁed by the study sites as term
(370/7 weeks GA), spontaneous preterm
(including preterm premature rupture of
membranes [PPROM]), or medically
indicated preterm births. Classiﬁcation of
preterm deliveries was subsequently
adjudicated by the chief medical ofﬁcer
(D.H.) at Sera Prognostics, Inc, who was
blinded to results from laboratory anal-
ysis. As indicated, discrepancies were
clariﬁed with the principal investigator at
the study site. The adjudication occurred
prior to locking down the validation
database and conducting laboratory and
statistical analysis.
Sample collection
Maternal blood was collected and pro-
cessed as follows: a 10-minute room
temperature clotting period, followed
by immediate refrigerated centrifugation
or placement in an ice-water bath at
4e8oC until centrifugation. Blood was
centrifuged within 2.5 hours of collec-
tion and 0.5 mL serum aliquots were
stored at 80oC until analyzed. Details
regarding sample accessioning can be
found in Supplementary Materials and
Methods.
Predictor development principles
Development of the insulin-like growth
factorebinding protein 4 (IBP4)/sex
hormoneebinding globulin (SHBG)
predictor included independent and
sequential discovery, veriﬁcation, and
validation steps consistent with Institute
of Medicine (IOM) guidelines for
best practices in “omics” research.18633.e2 American Journal of Obstetrics& GynecolAnalytical validation preceded clinical
validation sample analysis and included
assessment of inter- and intrabatch
precision, carry-over, and limit of
detection.
The validation nested case-control
analysis was performed on specimens
from 81 sPTD cases and controls in-
dependent of discovery and veriﬁca-
tion. Validation sPTD cases were the
last to be enrolled in PAPR and
included samples from 9 sites in total,
with 2 sites being unique to validation.
Validation cases and controls under-
went 100% on-site source document
veriﬁcation with each subject’s medical
record prior to mass spectrometry
(MS) analysis. This process ensured
that all subjects satisﬁed the inclusion
and exclusion criteria, as well as
conﬁrmed medical/pregnancy compli-
cations and GA at birth assignments for
all subjects at time of sample collection
and delivery. Detailed analysis pro-
tocols, including the validation study
design, analysis plan, and a blinding
protocol, were preestablished. Per-
sonnel were blinded to subject case,
control, and GA at birth data assign-
ments, with the exception of the di-
rector of clinical operations (DCO) and
clinical data manager. The data analysis
plan included prespeciﬁed validation
claims and a protocol for double inde-
pendent external analyses. Predictor
scores, calculated as described below,
were determined for all subject samples
by a blinded statistician and subse-
quently conﬁrmed by 2 external blin-
ded statisticians, 1 of whom was
university based (E. Mazzola) and the
other an industry consultant (P. Kear-
ney). Case, control, and GA data, linked
to the predictor scores by the DCO,
were then provided to the 2 external
statisticians for analysis. Area under the
receiver operating characteristic curve
(AUROC) and signiﬁcance testing re-
sults were then transferred back to the
DCO. Transfer of data incorporated the
use of the SUMPRODUCT19 function
to ensure data integrity. To provide an
audit trail of data from each subject
through to validation results, real-time
digital time-stamping was applied to
analytical data, plans, and reports.ogy MAY 2016Validation study design
In the primary analysis, cases were deﬁned
as subjects with deliveries due to PPROM
or spontaneous onset of labor with de-
livery <370/7 weeks GA. Controls were
subjects who delivered at 370/7 weeks
GA. Prior discovery and veriﬁcation ana-
lyses investigated 44 candidate biomarkers
using serum samples collected across
broad GA (170/7 through 256/7 weeks GA)
(Supplementary Materials and Methods).
Discovery and veriﬁcation identiﬁed an
optimal narrow GA at blood draw
(GABD) interval (190/7 through 216/7
weeks) and 2 proteins, IBP4, up-regulated
in sPTD cases, and SHBG, down-
regulated in sPTD cases, used in a ratio
(IBP4/SHBG) as the best predictor by
AUROC for sPTD (Supplementary
Materials and Methods). In discovery
and veriﬁcation, subjects without extreme
BMI values had improved classiﬁca-
tion performance by IBP4/SHBG
(Supplementary Results, Appendix).
Following discovery and veriﬁcation ana-
lyses, we proceeded to analytical and
clinical validation.
Validation sPTD cases totaled 18
subjects collected between 190/7 and
216/7 weeks GABD from a total available
of 81 subjects between 170/7 and 286/7
weeks GA. Sets of controls, comprising 2
controls per sPTD case matched by
GABD, were randomly selected using the
R statistical program (R 3.0.2)20,21 and
compared to the term delivery distribu-
tion as outlined in the 2012 National
Vital Statistics Report22 using a chi-
square test. Randomly created control
sets (in groups of 10) were examined for
sets yielding a P value approaching 1.0.
Our primary objective was to validate
the performance of the IBP4/SHBG
ratio as a predictor for sPTD using
AUROC.20,23 To control the overall
multiple testing error rate (a¼ 0.05), the
ﬁxed sequence approach24,25 was applied
to GABD increments within the optimal
interval (190/7 through 216/7 weeks GA)
identiﬁed in discovery and veriﬁcation
with and without the application of a
BMI stratiﬁcation (Supplementary
Materials and Methods). Signiﬁcance
was assessed by the Wilcoxon-Mann-
Whitney statistic that tests equivalence
to AUROC ¼ 0.5 (random chance).26,27
FIGURE 1
Distribution of subjects in the PAPR database
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A total of 5501 subjects were enrolled in the Proteomic Assessment of Preterm Risk (PAPR) study
between 170/7 and 286/7 weeks gestational age (GA). A number of subjects (120) were discontinued,
and another 146 subjects were lost to follow-up. Of the 5235 delivered subjects, 410 were excluded
from these analyses owing to progestogen use. Of the 4825 subjects remaining, 4292 delivered at
term, 248 experienced a spontaneous preterm delivery (sPTD), and 285 delivered preterm owing to
medical indications. Following preanalytic exclusion of 31 subjects, 217 sPTDs were available for
analysis and distributed among discovery, verification, and validation studies as shown.
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performance at GA boundaries other
than <370/7 vs 370/7 weeks GA (eg,
<360/7 vs 360/7, <350/7 vs 350/7),
cases and controls were redeﬁned as all
subjects below and equal to/above the
speciﬁc boundary, respectively.
Laboratory methods
A systems biology approach was
employed to generate a highly multi-
plexed multiple reaction monitoring(MRM) MS assay (Supplementary
Materials and Methods and
Supplementary Results). The validation
assay quantiﬁed proteotypic peptides
speciﬁc to predictor proteins IBP4 and
SHBG and other controls. Samples were
processed in batches of 32, which were
composed of clinical subjects (n ¼ 24),
pooled serum standards from healthy
nonpregnant donors (HGS) (n ¼ 3),
pooled serum standards from healthy
pregnant donors (pHGS) (n ¼ 3), andMAY 2016 Ameriphosphate-buffered saline that served as
process controls (n¼ 2). For all analyses,
serum samples were ﬁrst depleted of
high-abundance and nondiagnostic
proteins using MARS-14 immunode-
pletion columns (Agilent Technologies,
Santa Clara, CA), reduced with dithio-
threitol, alkylated with iodoacetamide,
and digested with trypsin. Heavy-labeled
stable isotope standard (SIS) peptides
(New England Peptide, Gardner, MA)
were then added to samples, which were
subsequently desalted and analyzed by
reversed-phase liquid chromatography
(LC)/MRM MS. SIS peptides were
used for normalization by generating
response ratios (RR), where the peak
area of a peptide fragment ion (ie, tran-
sition) measured in serum was divided
by that of the corresponding SIS transi-
tion spiked into the same serum sample.
The IBP4/SHBG predictor
The predictor score was deﬁned as the
natural log of the ratio of the IBP4 and
SHBG peptide transition response ratios:
S ¼ ln

RRIBP4
RRSHBG

;
where RR are the measured response
ratios of the respective peptides.
Results
Figure 1 summarizes the distribution of
study subjects in PAPR. Between March
2011 and August 2013, 5501 subjects
were enrolled. Clinical and demographic
data of the enrolled subjects by site are
included in Supplementary Materials
and Methods. As predeﬁned in the pro-
tocol, 410 subjects (6.7%) were excluded
from analysis owing to receiving pro-
gestogen therapy after the ﬁrst trimester
of pregnancy. An additional 120 subjects
(2.2%) were excluded owing to early
discontinuation, and 146 (2.7%) were
lost to follow-up. A total of 4825 subjects
were available for analysis. There were
533 PTDs: 248 (4.7%) spontaneous and
285 (5.9%) medically indicated. Com-
pared to those who delivered at term,
subjects with an sPTD were more likely
to have had 1 or more prior PTDs and to
have experienced bleeding after 12 weekscan Journal of Obstetrics& Gynecology 633.e3
TABLE 1
Maternal characteristics and pregnancy outcomes stratified by timing of delivery (sPTD and term)
Variables
PAPR study Entire validation cohort (170/7 to 286/7 weeks) Validated window (191/7 to 206/7 weeks)
Cases n (%)
(n ¼ 217)
Controls n (%)
(n ¼ 4292) P value
Cases n (%)
(n ¼ 81)
Controls n (%)
(n ¼ 162) P value
Cases n (%)
(n ¼ 18)
Controls n (%)
(n ¼ 36) P value
Maternal characteristics
Maternal age at enrollment, y .245 .239 .387
18e22 y 58 (26.7) 990 (23.1) 22 (27.2) 47 (29.0) 6 (33.3) 13 (36.1)
23e27 y 56 (25.8) 1222 (28.5) 17 (21.0) 41 (25.3) 6 (33.3) 9 (25.0)
28e32 y 54 (24.9) 1154 (26.9) 25 (30.9) 34 (21.0) 5 (27.8) 5 (13.9)
33e37 y 31 (14.3) 692 (16.1) 9 (11.1) 30 (18.5) 1 (5.6) 7 (19.4)
38 y or more 18 (8.3) 234 (5.5) 8 (9.9) 10 (6.2) 0 2 (5.6)
Mean 28 28 28 28 25 27
Median 27 27 28 27 25 25
Interquartile range 22e32 23e32 21e32 22e32 21e30 22e33
Body mass index, kg/m2 .380 .802 .959
Less than 18.5 10 (4.7) 129 (3.1) 1 (1.3) 2 (1.3) 0 0
18.5e24.9 78 (36.8) 1789 (42.3) 25 (31.3) 55 (34.6) 8 (44.4) 16 (45.7)
25.0e29.9 54 (25.5) 1091 (25.8) 26 (32.5) 46 (28.9) 4 (22.2) 9 (25.7)
30.0e34.9 39 (18.4) 617 (15.6) 17 (21.3) 25 (15.7) 3 (16.7) 4 (11.4)
35.0e39.9 17 (8.0) 320 (7.6) 6 (7.5) 17 (10.7) 2 (11.1) 5 (14.3)
Greater than 40.0 14 (6.6) 286 (6.7) 5 (6.3) 14 (8.8) 1 (5.6) 1 (2.9)
Mean 27.8 27.5 28.4 29.1 28.2 27.4
Median 26.5 25.7 27.4 27.8 26.5 27
Interquartile range 22.7e31.8 22.3e31.1 23.6e32.0 23.4e32.4 23.8e33.7 22.3e30.6
Education level <.0002 .201 .263
Graduate degree 13 (6.0) 461 (10.9) 6 (7.7) 14 (8.7) 0 2 (5.7)
College diploma 34 (15.8) 701 (16.6) 10 (12.6) 22 (13.8) 2 (11.1) 5 (14.3)
Some college 51 (23.7) 936 (22.2) 19 (24.0) 23 (14.4) 1 (5.6) 5 (14.3)
High school diploma/equivalent 46 (21.4) 1032 (24.5) 16 (20.2) 50 (31.3) 5 (27.8) 14 (40.0)
Some high school 53 (24.6) 774 (18.4) 25 (31.6) 36 (22.5) 9 (50.0) 6 (17.1)
9th grade or less 12 (5.8) 292 (6.9) 3 (3.8) 14 (8.7) 1 (5.6) 3 (8.6)
Other 6 (2.8) 23 (0.6) 0 1 (0.6) 0 0
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TABLE 1
Maternal characteristics and pregnancy outcomes stratified by timing of delivery (sPTD and term) (continued)
Variables
PAPR study Entire validation cohort (170/7 to 286/7 weeks) Validated window (191/7 to 206/7 weeks)
Cases n (%)
(n ¼ 217)
Controls n (%)
(n ¼ 4292) P value
Cases n (%)
(n ¼ 81)
Controls n (%)
(n ¼ 162) P value
Cases n (%)
(n ¼ 18)
Controls n (%)
(n ¼ 36) P value
Ethnicity .157 .035 .844
Hispanic or Latino 89 (41.0) 1557 (36.3) 27 (33.3) 77 (47.5) 7 (38.9) 15 (41.7)
Non-Hispanic or Latino 128 (59.0) 2735 (63.7) 54 (66.7) 85 (52.5) 11 (61.1) 21 (58.3)
Race .887 .811 .319
American Indian/Alaskan Native 1 (0.5) 29 (0.7) 0 2 (1.2) 0 1 (2.8)
Asian 4 (1.8) 131 (3.1) 1 (1.2) 1 (0.6) 0 1 (2.8)
Black or African-American 45 (20.7) 838 (19.5) 19 (23.5) 37 (22.8) 2 (11.1) 11 (30.6)
Native Hawaiian or other
Pacific Islander
0 12 (0.30) 0 2 (1.2) 0 1 (2.8)
White 156 (71.9) 3101 (72.3) 58 (71.6) 114 (70.4) 16 (88.9) 22 (61.1)
Other 11 (5.1) 193 (4.5) 3 (3.7) 6 (3.7) 0 0
Obstetrical characteristics
Primigravida 64 (29.5) 1212 (28.2) .689 27 (33.3) 39 (24.1) .126 5 (27.8) 8 (22.2) .652
Multigravida 153 (70.5) 3080 (71.8) 54 (66.7) 123 (75.9) 13 (72.2) 28 (77.8)
Number of prior full-term
deliveries
.007 .326 .790
1 or more 113 (73.8) 2538 (82.4) 40 (74.5) 102 (82.9) 10 (76.9) 22 (78.6)
None 40 (26.2) 542 (17.6) 13 (24.5) 21 (17.1) 3 (23.1) 6 (21.4)
Number of prior sPTDs <.0001 .221 .524
1 or more 35 (22.9) 339 (11.0) 9 (16.7) 11 (8.9) 1 (7.7) 6 (21.4)
None 118 (77.1) 2741 (89.0) 45 (83.3) 112 (91.1) 12 (92.3) 22 (78.6)
Lifestyle characteristics
Smoking .412 .719 1.000
Yes 34 (15.7) 588 (13.7) 15 (18.5) 27 (16.7) 3 (16.7) 6 (16.7)
No 183 (84.3) 3704 (86.3) 66 (81.5) 135 (83.3) 15 (83.3) 30 (83.3)
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TABLE 1
Maternal characteristics and pregnancy outcomes stratified by timing of delivery (sPTD and term) (continued)
Variables
PAPR study Entire validation cohort (170/7 to 286/7 weeks) Validated window (191/7 to 206/7 weeks)
Cases n (%)
(n ¼ 217)
Controls n (%)
(n ¼ 4292) P value
Cases n (%)
(n ¼ 81)
Controls n (%)
(n ¼ 162) P value
Cases n (%)
(n ¼ 18)
Controls n (%)
(n ¼ 36) P value
Illicit drugs .283 .628 .739
Yes 16 (7.4) 242 (5.6) 6 (7.4) 15 (9.3) 2 (11.1) 3 (8.3)
No 201 (92.6) 4050 (94.4) 75 (92.6) 147 (90.7) 16 (88.9) 33 (91.7)
Alcohol .096 .628 .278
Yes 20 (9.2) 273 (6.4) 6 (7.4) 15 (9.3) 4 (22.2) 4 (11.1)
No 197 (90.8) 4018 (93.6) 75 (92.6) 147 (90.7) 14 (77.8) 32 (88.9)
Alcohol use .108 .592 .278
Yes (amount unknown) 3 (1.4) 39 (0.9) 0 2 (1.2) 0 0
Social (occasional) 16 (7.4) 230 (5.4) 6 (7.4) 13 (8.0) 4 (22.2) 4 (11.1)
Heavy (daily) 1 (0.5) 4 (0.09) 0 0 0 0
No 197 (90.8) 4018 (93.6) 75 (92.6) 147 (90.7) 14 (77.8) 32 (88.9)
Medical characteristics
Bleeding during pregnancy
after 12 wk
.006 .360 .308
Yes 21 (9.7) 228 (5.3) 7 (8.6) 9 (5.6) 0 2 (5.6)
No 196 (90.3) 4064 (94.7) 74 (91.4) 153 (94.4) 18 (100.0) 34 (94.4)
Comparisons of clinical data between cases and controls were performed using chi-square test, Fisher exact test, or Mann-Whitney test, as appropriate (SAS System 9.4 and R 3.1.0).
Missing values are excluded in the frequency tables.
N, number of subjects; sPTD, spontaneous preterm delivery.
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FIGURE 2
ROC performance of the IBP4/
SHBG predictor in validation
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Receiver operating characteristic performance
in the validation sample set. The plot graphs
sensitivity (true-positive rate) vs 1-specificity
(false-positive rate), where sPTD cases are
defined as delivery <370/7 weeks GA and term
controls are defined as delivery 370/7 weeks
GA. The AUROC corresponds to 0.75 for the
BMI-stratified validation subjects, (>22 and
37 kg/m2) comprising 35 subjects: 12 sPTD
cases and 23 term controls.
Saade et al. Validation of a preterm delivery predictor. Am J
Obstet Gynecol 2016.
TABLE 2
Performance of IBP4/SHBG predictor
GA boundary AUC (95% CI) Sensitivity Specificity OR (95% CI)
<37 vs 37 0.75 (0.56e0.91) 0.75 0.74 5.04 (1.4e18)
<36 vs 36 0.79 (0.53e0.99) 0.83 0.83 17.33 (2.2e138)
<35 vs 35 0.93 (0.81e1.00) 1 0.83 34.47 (1.7e699)
AUC, area under the curve; CI, confidence interval; GA, gestational age; OR, odds ratio.
Saade et al. Validation of a preterm delivery predictor. Am J Obstet Gynecol 2016.
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(Table 1). Characteristics of sPTD cases
and term controls selected for the overall
validation cohort were not signiﬁcantly
different from each other, with the
exception that there were signiﬁcantly
more Hispanic controls (47.5% vs
33.3%, P ¼ .035). Similarly, subjects
selected for the validated window were
largely representative of the study cohort
as a whole (Table 1).
Validation analysis
In discovery and veriﬁcation analyses,
the ratio of IBP4 (up-regulated in
sPTD)/SHBG (down-regulated in sPTD)
and the interval between 190/7 and 216/7
weeks GA was identiﬁed as the
best-performing sPTD predictor by
AUROC and GA interval, respectively
(Supplementary Results). For validation,
a predeﬁned ﬁxed sequence approach
validated the IBP4/SHBG predictor with
and without BMI stratiﬁcation, with
optimal performance identiﬁed for the
GA interval of 191/7 through 206/7 weeks.
Without taking BMI into consideration,validated performance was AUROC ¼
0.67 (95% conﬁdence interval [CI],
0.52e0.81) for 18 sPTD cases and 36
term controls (Supplementary Results).
However, as expected, performance was
improved with a BMI stratiﬁcation of
>22 and 37 kg/m2, which corre-
sponded to an AUROC of 0.75 for 12
sPTD cases and 23 term controls (95%
CI, 0.56e0.91) (Figure 2; and
Supplementary Results). More detailed
characterization of BMI stratiﬁcation
can be found in the Supplementary
Results. Performance measures of
sensitivity, speciﬁcity, AUROC, and odds
ratios (ORs) were determined at varied
case-vs-control boundaries (Table 2).
For sPTD vs term birth (<370/7 vs370/7
weeks), the sensitivity and speciﬁcity was
0.75 and 0.74, respectively, with anORof
5.04 (95% CI, 1.4e18). The results at
other boundaries are summarized in
Table 2. Accuracy of the test improved at
lower GA boundaries.
The prevalence adjusted positive pre-
dictive value (PPV), a measure of clinical
risk, is shown as a function of predictor
score in Figure 3. Stratiﬁcation of sub-
jects with increasing predictor scores
occurs as PPV increases from a back-
ground value (population sPTD rate of
7.3% for singleton births in the United
States)28 to relative risks of 2 (14.6%)
and 3 (21.9%) (dashed lines) and
higher (Figure 3). The distribution of
IBP4/SHBG predictor score values for
subjects color-coded by GA at birth
category are shown in box plots in
Figure 3. The earliest sPTD cases (<350/7
weeks GA) have higher predictor scores
than late-term controls (390/7 weeks
GA), while the scores for late sPTD cases
(350/7 through <370/7 weeks GA)
overlap with early-term controls (370/7MAY 2016 Amerithrough <390/7 weeks GA) (Figure 3).
Using the BMI-stratiﬁed risk curve in
Figure 3, validation subjects were iden-
tiﬁed as high or low risk according to a
predictor score cutoff corresponding to
2 relative risk (PPVof 14.6%, predictor
score ¼ 1.36655). The rates of births
for the high- and low-risk groups were
then displayed as events in a Kaplan-
Meier analysis (Figure 4). From this
analysis, those classiﬁed as high risk
generally delivered earlier than those
classiﬁed as low risk (P ¼ .0004).
Postvalidation analyses
Predictor performance was measured
using a combination of subjects from the
blinded veriﬁcation (Supplementary
Materials and Methods) and validation
analyses within the optimal BMI and GA
interval. The ROC curve for the com-
bined sample set (16 sPTD cases and 34
term controls) is shown and corresponds
to an AUROC of 0.72 (95% CI,
0.51e0.8) (Figure 5).
Comment
Using an “omics” approach, we devel-
oped a maternal serum predictor
comprising the ratio of IBP4/SHBG
levels at 19e20 weeks with a BMI in-
terval of >22 and 37 kg/m2 that iden-
tiﬁed 75% of women destined for sPTD.
Prior history of sPTD8,29 and cervical
length measurements9,30 are considered
the best measures of clinical risk to date;
however, either individually or in com-
bination, they fail to predict the majority
of sPTDs.
An ideal sPTD prediction tool would
be minimally invasive; would be per-
formed early in gestation, coinciding
with timing of routine obstetrical visits;
and would accurately identify those atcan Journal of Obstetrics& Gynecology 633.e7
FIGURE 3
Stratification of validation subjects by the IBP4/SHBG predictor
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Prevalence-corrected positive predictive value (PPV) was plotted as a function of predictor score for
the validation samples within the validated blood draw window and BMI >22 and 37 kg/m2 (35
subjects: 12 sPTD cases and 23 term controls). Horizontal dashed lines identify the average pop-
ulation risk of 7.3%, calculated as 75% of the singleton rate of PTD of 9.71%,28 and relative risks of
2 (14.6%) and 3 (21.9%). Vertical dashed lines identify corresponding predictor scores. The
confidence interval about the PPV curve (gray shaded area) was estimated using 150 subjects from
postdiscovery datasets (verification, validation, and prevalence controls) as described in
Supplementary Materials and Methods. Confidence intervals about the PPV were calculated with the
normal approximation of the error for binomial proportions.54 Box plots at the foot of the figure
correspond to the distributions of predictor scores for subjects in the different gestational age at birth
(GAB) categories identified in the legend. The PPV curve and the box plots share the same predictor
score axis.
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Original Research OBSTETRICS ajog.orghighest risk. Current “omics” studies
suggest that perturbations in the physi-
ological state of pregnancy can be
detected in maternal serum analytes
measured in sPTD subjects. “Omics”
discovery studies in PTD have in-
cluded proteomic,10,12,13,31-34 tran-
scriptomic,35-37 genomic,38-42 and
metabolomic43 approaches. However, to
date, none of these approaches has pro-
duced validated testing methods to reli-
ably predict the risk of sPTD in
asymptomatic women.
The current investigation builds on
the previous approaches in several ways.
We completed a large prospective and
contemporaneous clinical study that
allowed independent discovery, veriﬁ-
cation, and validation analyses, while
adhering to IOM guidelines regarding633.e8 American Journal of Obstetrics& Gynecol“omics” test development. We con-
structed a large and standardized multi-
plexed proteomic assay to probe
biological pathways of relevance in
pregnancy. Our study size and relatively
broad blood collection window (170/7
through 286/7 weeks GA) also enabled
the identiﬁcation of a GA interval in
which there were marked alterations in
protein concentrations between sPTD
cases and term controls. Use of a low-
complexity predictor model (ie, the ra-
tio of 2 proteins) limited the pitfalls of
over-ﬁtting.
Application of the proteomic assay
and model building led to the identiﬁ-
cation of a pair of critical proteins (IBP4
and SHBG) with consistently good pre-
dictive performance for sPTD. Despite
the challenges of building a classiﬁer forogy MAY 2016a condition attributed to multiple etiol-
ogies, the predictor demonstrated good
performance in 3 independent studies at
a cutoff of <370/7 vs 370/7 weeks GA.
Importantly, accuracy of the predictor
improved for earlier sPTDs (eg, <350/7
weeks GA), enabling the detection of
those sPTDs with the greatest potential
for morbidity. Subjects determined to be
at high risk for sPTD using the IBP4/
SHBG predictor delivered signiﬁcantly
earlier than subjects identiﬁed as low
risk. Our ﬁndings suggest that IBP4 and
SHBG may perform important func-
tions related to the etiologies of sPTD
and/or act as convergence points in
relevant biological pathways.
IBP4 is a member of a family of
insulin-like growth factor binding pro-
teins (IBPs) that negatively regulate the
insulin-like growth factors IGF1 and
IGF2.44 IBP4 is expressed by syncytio-
trophoblasts45 and is the dominant IBP
expressed by extravillous trophoblasts.46
Compared to normal pregnancies,
maternal IBP4 levels in early pregnancy
are higher in pregnancies complicated by
fetal growth restriction and preeclamp-
sia.46 We speculate that elevated
maternal serum IBP4 levels may reﬂect
abnormal placentation and thus an
increased risk of sPTD.
SHBG regulates the availability of
biologically active unbound steroid
hormones.47 Plasma SHBG levels in-
crease 5- to 10-fold during pregnancy,48
and evidence exists for extrahepatic
expression, including placental tropho-
blastic cells.49 Physiologically, SHBG
levels negatively correlate with tri-
glycerides, insulin levels, and BMI.50
BMI’s effect on SHBG levels may
explain, in part, the improved predictive
performance with BMI stratiﬁcation.
Intraamniotic infection and inﬂam-
mation have been associated with PTD,
as have increased levels of proin-
ﬂammatory cytokines, including TNF-a
and IL1-b.51,52 SHBG transcription in
liver is suppressed by IL1-b and NF-kB-
mediated TNF-a signaling,50 a pathway
implicated in initiation of normal and
abnormal labor.53 Lower levels of SHBG
in women destined for sPTD may be a
result of infection and/or inﬂammation.
Hence, SHBG may be critical for control
FIGURE 4
Kaplan-Meier estimator of high- and low-risk groups
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IBP4/SHBG predictor. Subjects at or above 2 the background risk (14.6%) were considered high
risk, while those below 2 were considered low risk. Curves depict the rate of events, which are
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FIGURE 5
Predictor performance in
combined datasets
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ajog.org OBSTETRICS Original Researchof androgen and estrogen action in the
placental-fetal unit in response to up-
stream inﬂammatory signals.
Despite the strengths of our study re-
sults, these ﬁndings need to be evaluated
in the context of the study limitations.
Universal transvaginal ultrasound mea-
surement of cervical length (CL) was not
performed routinely at the majority of
our study centers and was available for
fewer than one-third of study subjects. It
will be of interest to assess whether CL
measurements improve upon the pro-
teomic predictor in future studies or,
alternatively, if risk stratiﬁcation by the
IBP4/SHBG classiﬁer identiﬁes women
that beneﬁt most from serial CL mea-
surements. There was an insufﬁcient
number of women with prior preterm
delivery who were not being treated with
progesterone to allow inclusion of thisvariable in the analysis. Therefore,
women with prior sPTD should be
treated according to national guidelines,
which include prophylactic treatment
with 17-alpha hydroxyprogesterone
caproate. Owing to sample size limita-
tions, a more complete assessment of
confounders will require future studies.
Finally, it will be intriguing to investigate
the performance of the molecular pre-
dictor together with a BMI variable or
perhaps in combination with other
medical/pregnancy history and socio-
demographic characteristics.
In conclusion, a predeﬁned predictive
test for sPTD based on serum measure-
ments of IBP4 and SHBG in asymptom-
atic parous and nulliparous women was
validated in a completely independent set
of subjects. Further functional studies on
these proteins, their gene regulation, andMAY 2016 Amerirelated pathways may help to elucidate
the molecular and physiological un-
derpinnings of sPTD. Application of this
predictor should enable early and sensi-
tive detection of women at risk of sPTD.
This early detection may improve preg-
nancy outcomes through increased clin-
ical surveillance as well as accelerate the
development of clinical interventions for
PTD prevention. n
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Appendix
SupplementaryMaterials and
Methods
Discovery and verification subjects
Discovery and veriﬁcation subjects were
derived from the Proteomic Assessment
of Preterm Risk (PAPR) study described
in the Materials and Methods section.
Discovery and verification
principles
Spontaneous preterm delivery (sPTD)
cases were deﬁned as described in Ma-
terials and Methods.
Discovery and veriﬁcation of the
predictor was conducted according to
guidelines for best practices in “omics”
research.1 Nested case-control analyses
used sample sets completely indepen-
dent of each other. Cases and controls
selected for discovery and veriﬁcation
underwent central review for within-
subject data discrepancies; no source
document veriﬁcation (SDV) with the
medical record was performed. All sPTD
cases and controls for discovery and
veriﬁcation were individually adjudi-
cated by the chief medical ofﬁcer, and
discrepancies were clariﬁed with the
principal investigator at the clinical site.
Detailed analysis protocols, including
study designs, analysis plans, and a
veriﬁcation blinding protocol, were
preestablished. Laboratory and data
analysis personnel were blinded to
veriﬁcation subject’s case, control, and
gestational age (GA) data assignments.
Predictor scores, calculated as described
below, were assigned to all subjects by an
internal blinded statistician. Case, con-
trol, and GAdata, linked to the predictor
scores by the director of clinical opera-
tions (DCO), were provided to an in-
dependent university-based external
statistician for analysis. Area under the
receiver operating characteristic curve
(AUROC) results were then transferred
back to the DCO. Transfer of data uti-
lized a SUMPRODUCT2 function in
Excel to ensure maintenance of data
integrity. To provide an audit trail of
data from subjects through to veriﬁca-
tion results, digital time-stamping was
applied to analytical data, plans, and
reports.
Discovery and verification study
design
One hundred and thirty-six sPTD cases
were randomly distributed between
discovery (n¼ 86) and veriﬁcation (n¼
50), collected from 170/7 through 286/7
weeks GA at blood draw (GABD)
(Supplementary Table 1). Subjects used
in discovery and veriﬁcation were
completely independent of each other
and independent from those used in
validation. Matched controls were
identiﬁed for sPTD cases in discovery
and veriﬁcation, as described in Mate-
rials and Methods.
Prevalence analyses
Following discovery, veriﬁcation, and
validation analyses, additional term
controls, not used in prior studies, were
selected from the PAPR database and
processed in the laboratory using the
multiple reaction monitoring (MRM)
mass spectrometry (MS) assay applied in
validation anddescribed inMaterials and
Methods. Using the Sampling package in
R statistical software (version 3.0.3),3,4
sets of 187 subjects, without source data
monitoring, were randomly selected
from the validated GABD interval and
compared via univariate statistical ana-
lyses (chi-square test) against the gesta-
tional age at birth (GAB) data from the
2012 National Vital Statistics Report
(NVSR).5 Sets of controls most closely
approximating the distribution of de-
liveries in the 2012 NVSR based on the
best P value (approaching 1.0 with
minimum acceptable value of .950) were
then selected for comparison against the
body mass index (BMI) distribution in
the PAPR study as a whole. Using uni-
variate statistical analyses (chi-square
test) against the BMI data from the PAPR
study database, the sets of controls most
closely approximating the distribution of
BMI (approaching 1.0 with minimum
acceptable value of .950) and the distri-
bution of delivery timing in the NVSR
were selected and compared to the
GABD of the validated blood draw
samples. The set that most closely
approximated all 3 distributions was
selected as the subject set for the preva-
lence study. Predictor score values for
veriﬁcation, validation, and prevalence
within the validation GABD interval and
BMI restriction totaled 150 subjects. This
composite dataset was used to obtain the
best estimates of conﬁdence intervals
about the positive predictive value (PPV)
curve in Figure 3. Conﬁdence intervals
about the PPV curve were calculated
with the normal approximation of the
error for binomial proportions.6
Sample accessioning
Biospecimen accessioning procedures
included: (1) immediate 2-dimensional
barcode labeling by study personnel on
site following specimen processing, (2)
visual inspection that specimens were
received frozen on dry ice and entry into
a computerized database upon accession
by Sera Prognostics, (3) veriﬁcation of
specimen temperature throughout the
shipping process from temperature
tracking monitors, (4) comparison of
specimen IDs from barcodes and site
shipment inventories, and (5) immedi-
ate transfer of specimens from shipping
containers (with dry ice) into 80C
freezers.
Laboratory methods
A systems biology approach was
employed to generate a highly multi-
plexed MRM MS assay by iterative
application of literature curation, tar-
geted and untargeted proteomic dis-
covery, and small-scale MRM MS
analyses of subject samples. Initial
curation was done manually and inde-
pendently by 3 individuals using search
terms including, but not limited to:
preterm birth, pre-term birth, pre-
eclampsia, placenta, placental gene
expression, labor, preterm labor, pre-
mature rupture of membranes,
PPROM, myometrial gene expression,
and intra-amniotic infection. In subse-
quent rounds, larger-scale literature
searches were performed using publicly
available data obtained from PubMed. A
Perl program executed keyword searches
through National Center for Biotech-
nology Information’s public application
programming interface, then down-
loaded the result sets in XML format.
The resultant XML ﬁles were parsed by
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another Perl script yielding a list of
PubMed identiﬁers (IDs). These
PubMed IDs were then cross-referenced
to Entrez Gene IDs using a gene2-
pubmed ﬁle. The Entrez Gene IDs were
then ﬁltered against a list of extracellular
proteins annotated in Uniprot. The
mature MRM MS assay, measuring 147
proteins, was applied in discovery and
veriﬁcation studies. For all analyses,
serum samples were processed in the
laboratory as described in Materials and
Methods. Aliquots of pooled serum
controls (pHGS) were used to calculate
the interbatch analytical coefﬁcient of
variation for insulin-like growth
factorebinding protein 4 (IBP4) and sex
hormoneebinding globulin (SHBG).
Normal ranges
In an analytical validation study, the
details of which will be published sepa-
rately, acceptable performance of each
analyte was demonstrated for a range of
protein responses. All clinical validation
samples had protein responses within
this range. Analyses of 1163 patient
samples were used to develop historical
means and standard deviations (SD) for
protein responses. Sample acceptability
criteria were set at 2.5 SD from the
historical mean.
General predictor development
strategy
A strategy was developed to avoid over-
ﬁtting and to overcome the dilution of
biomarker performance expected across
broad GA ranges owing to the dynamic
nature of protein expression during
pregnancy. Ratios of up-regulated over
down-regulated analyte intensities were
employed in predictor development.
Such “reversals” are similar to the top-
scoring pair and 2-gene classiﬁer strate-
gies.7,8 This approach allowed ampliﬁ-
cation of the diagnostic signal and self-
normalization, as both proteins in a
“reversal” underwent the same pre-
analytical and analytical processing steps.
As a strategy to normalize peptide in-
tensity measures in complex proteomics
workﬂows, reversals are also similar to a
recently introduced approach termed
endogenous protein normalization
(EPN).9,10 The number of candidate
analytes used for model building was
reduced by analytic criteria. Analytic ﬁl-
ters included cutoffs for analytical preci-
sion, intensity, evidence of interference,
sample processing order dependence,
and preanalytical stability. The total
number of analytes in any one predictor
was limited to a single reversal, thus
avoiding complex mathematical models.
Predictor scores were deﬁned as the
natural log of a single reversal value, in
which the reversal itself was a response
ratio (deﬁned inMaterials andMethods).
Lastly, predictive performance was
investigated in narrow overlapping 3-
week intervals of gestation.
Receiver operating characteristic
curves
AUROC values and associated P values
were calculated for reversals as described
in Materials and Methods. The distri-
bution and mean value for predictor
AUROC in the combined discovery and
veriﬁcation set was calculated using a
bootstrap sampling performed itera-
tively by selecting random sets of sam-
ples with replacement.11 The total
number of selected samples at each
iteration corresponded to the total
available in the starting pool.
Supplementary Results
Discovery, veriﬁcation, and validation
subject characteristics are summarized in
Supplementary Table 1. Distribution of
subjects and select clinical variables by
site are summarized in Supplementary
Table 2. The percentage of subjects
with 1 or more prior sPTDs in discovery
sPTD cases were higher than in veriﬁca-
tion or validation, and other character-
istics were largely consistent across the
studies.
Discovery and verification analyses
Forty-four proteins were either up- or
down-regulated in overlapping 3-week
GA intervals and passed analytic ﬁlters
(Supplementary Figure 1,
Supplementary Table 3). All possible re-
versals were formed from the ratio of up-
over down-regulated proteins and pre-
dictive performance by AUROC was
tested in samples in each of the over-
lapping 3-week GA intervals using an R
script. Performance for a subset of re-
versals displaying representative patterns
is shown in Supplementary Figure 2.
Waves of performance were evident:
IBP4/SHBG and APOH/SHBG reversals
possessed better AUROC values in early
windows, while ITIH4/BGH3 and PSG2/
BGH3 peaked later in gestation
(Supplementary Figure 2). Some re-
versals had a consistent but moderate
performance across the entire GA range
(PSG2/PRG2) (Supplementary Figure 2).
The top-performing reversal overall,
formed from the up-regulated protein
IBP4 and the down-regulated protein
SHBG (IBP4/SHBG), had an AUROC ¼
0.74 in the interval from 190/7 through
216/7 (Supplementary Figure 2). AUROC
performance of the IBP4/SHBG predic-
tor increased to 0.79 when subjects
were stratiﬁed by prepregnancy BMI<35
kg/m2 (Supplementary Table 4). Because
of its consistently strong performance
early in gestation (ie, 170/7 through 226/7
weeksGA) (Supplementary Figure 2) and
potentially desirable clinical utility, the
IBP4/SHBG predictor was selected for
veriﬁcation analysis.
The blinded IBP4/SHBG AUROC
performance on veriﬁcation samples
was 0.77 and 0.79 for all subjects and
BMI-stratiﬁed subjects, respectively, in
good agreement with performance
obtained in discovery (Supplementary
Table 4). Following blinded veriﬁca-
tion, discovery and veriﬁcation sam-
ples were combined for a bootstrap
performance determination. A
mean AUROC of 0.76 was obtained
from 2000 bootstrap iterations
(Supplementary Figure 3).
BMI validation analyses
The performance of the IBP4/SHBG
predictor was evaluated at several cutoffs
of BMI in the validation samples
(Supplementary Table 5). AUROC-
measured performance modestly
improved by elimination of either very
high (eg, >37 kg/m2) or low BMI (eg,
22 kg/m2). Stratiﬁcation by a combi-
nation of those 2 cutoffs gave an AUROC
of 0.75 (Supplementary Table 5).
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SUPPLEMENTARY TABLE 1
Maternal characteristics and pregnancy outcomes stratified by timing of delivery (sPTD and term)
Variables
Discovery Verification Validation
Discovery vs
verification
Discovery vs
validation
Verification vs
validation
Case n (%)
(n ¼ 86)
Control n (%)
(n ¼ 172) P value
Case n (%)
(n ¼ 50)
Control n (%)
(n ¼ 150) P value
Case n (%)
(n ¼ 81)
Control n (%)
(n ¼ 162) P value P value P value P value
Maternal characteristics
Maternal age at enrollment, y .245 .977 .239 .644 .594 .427
18e22 y 26 (30.2) 39 (22.7) 10 (20.0) 21 (21.0) 22 (27.2) 47 (29.0)
23e27 y 25 (29.1) 58 (33.7) 14 (28.0) 26 (26.0) 17 (21.0) 41 (25.3)
28e32 y 14 (16.3) 44 (25.6) 15 (30.0) 27 (27.0) 25 (30.9) 34 (21.0)
33e37 y 14 (16.3) 23 (13.4) 8 (16.0) 20 (20.0) 9 (11.1) 30 (18.5)
38 y or more 7 (8.1) 8 (4.6) 3 (6.0) 6 (6.0) 8 (9.9) 10 (6.2)
Mean 28 28 29 29 28 28
Median 26 27 28 29 28 27
Interquartile range 22e32 23e31 24e32 23e34 21e32 22e32
Body mass index, kg/m2 .528 .722 .802 .869 .501 .729
Less than 18.5 4 (4.8) 8 (4.7) 5 (10.4) 6 (6.0) 1 (1.3) 2 (1.3)
18.5e24.9 33 (39.3) 82 (48.5) 20 (41.7) 39 (39.0) 25 (31.3) 55 (34.6)
25.0e29.9 20 (23.8) 33 (19.5) 8 (16.7) 25 (25.0) 26 (32.5) 46 (28.9)
30.0e34.9 14 (16.7) 22 (13.0) 8 (16.7) 14 (14.0) 17 (21.3) 25 (15.7)
35.0e39.9 8 (9.5) 9 (5.3) 3 (6.3) 10 (10.0) 6 (7.5) 17 (10.7)
Greater than 40.0 5 (5.9) 15 (9.0) 4 (8.3) 6 (6.0) 5 (6.3) 14 (8.8)
Mean 27.5 26.9 27.2 27.4 28.4 29.1
Median 26.1 24.6 24.8 25.8 27.4 27.8
Interquartile Range 22.4e32.2 21.8e30.4 22e31.6 22e32.5 23.6e32.0 23.4e32.4
Education level .220 .204 .201 .153 .161 .115
Graduate degree 5 (5.8) 15 (8.7) 2 (4.0) 16 (16.2) 6 (7.7) 14 (8.7)
College diploma 10 (11.6) 37 (21.5) 14 (28.0) 20 (20.2) 10 (12.6) 22 (13.8)
Some college 19 (22.1) 41 (23.8) 13 (26.0) 18 (18.2) 19 (24.0) 23 (14.4)
High school
diploma/equivalent
23 (26.7) 35 (20.4) 7 (14.0) 19 (19.2) 16 (20.2) 50 (31.3)
Some high school 18 (20.9) 31 (18.0) 10 (20.0) 19 (19.2) 25 (31.6) 36 (22.5)
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SUPPLEMENTARY TABLE 1
Maternal characteristics and pregnancy outcomes stratified by timing of delivery (sPTD and term) (continued)
Variables
Discovery Verification Validation
Discovery vs
verification
Discovery vs
validation
Verification vs
validation
Case n (%)
(n ¼ 86)
Control n (%)
(n ¼ 172) P value
Case n (%)
(n ¼ 50)
Control n (%)
(n ¼ 150) P value
Case n (%)
(n ¼ 81)
Control n (%)
(n ¼ 162) P value P value P value P value
9th grade or less 6 (7.0) 10 (5.8) 3 (6.0) 7 (7.1) 3 (3.8) 14 (8.7)
Other 5 (5.8) 3 (1.7) 1 (2.0) 0 0 1 (0.6)
Ethnicity .210 .343 .035 .116 .564 .277
Hispanic or Latino 40 (46.5) 66 (38.4) 22 (44.0) 36 (36.0) 27 (33.3) 77 (47.5)
Non-Hispanic or Latino 46 (53.5) 106 (61.6) 28 (56.0) 64 (64.0) 54 (66.7) 85 (52.5)
Race .173 .373 .811 .390 .602 .615
American Indian/Alaskan
Native
1 (1.1) 0 0 0 0 2 (1.2)
Asian 1 (1.1) 9 (5.2) 2 (4.0) 3 (3.0) 1 (1.2) 1 (0.6)
Black or African-American 20 (23.3) 41 (23.8) 6 (12.0) 21 (21.0) 19 (23.5) 37 (22.8)
Native Hawaiian or other
Pacific Islander
0 0 0 0 0 2 (1.2)
White 62 (72.1) 112 (65.1) 36 (72.0) 70 (70.0) 58 (71.6) 114 (70.4)
Other 2 (2.3) 10 (5.8) 6 (12.0) 6 (6.0) 3 (3.7) 6 (3.7)
Obstetrical characteristics
Primigravida 21 (24.4) 52 (30.2) .328 16 (32.0) 33 (33.0) .902 27 (33.3) 39 (24.1) .126 .400 .724 .272
Multigravida 65 (75.6) 120 (69.8) 34 (68.0) 67 (67.0) 54 (66.7) 123 (75.9)
Number of prior full-term
deliveries
.141 .673 .326 .208 .134 .221
1 or more 45 (71.4) 98 (81.7) 25 (73.5) 55 (82.1) 40 (74.5) 102 (82.9)
None 18 (28.6) 22 (18.3) 9 (26.5) 12 (17.9) 13 (24.5) 21 (17.1)
Number of prior sPTDs .060 .188 .221 .014 .018 .056
1 or more 17 (26.2) 14 (11.7) 9 (26.5) 9 (13.4) 9 (16.7) 11 (8.9)
None 48 (73.8) 106 (88.3) 25 (73.5) 58 (86.6) 45 (83.3) 112 (91.1)
Lifestyle characteristics
Smoking .329 .728 .719 .328 .365 .622
Yes 12 (14.0) 17 (9.9) 7 (14.0) 12 (12.0) 15 (18.5) 27 (16.7)
No 74 (86.0) 155 (90.1) 43 (86.0) 88 (88.8) 66 (81.5) 135 (83.3)
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SUPPLEMENTARY TABLE 1
Maternal characteristics and pregnancy outcomes stratified by timing of delivery (sPTD and term) (continued)
Variables
Discovery Verification Validation
Discovery vs
verification
Discovery vs
validation
Verification vs
validation
Case n (%)
(n ¼ 86)
Control n (%)
(n ¼ 172) P value
Case n (%)
(n ¼ 50)
Control n (%)
(n ¼ 150) P value
Case n (%)
(n ¼ 81)
Control n (%)
(n ¼ 162) P value P value P value P value
Illicit drugs .030 .824 .628 .125 .491 .794
Yes 6 (7.0) 2 (1.1) 4 (8.0) 7 (7.0) 6 (7.4) 15 (9.3)
No 80 (93.0) 170 (98.8) 46 (92.0) 93 (93.0) 75 (92.6) 147 (90.7)
Alcohol .147 .171 .628 .052 .494 .781
Yes 10 (11.6) 11 (6.4) 4 (8.0) 3 (3.0) 6 (7.4) 15 (9.3)
No 76 (86.1) 161 (93.6) 46 (92.0) 97 (97.0) 75 (92.6) 147 (90.7)
Alcohol use .410 .379 .592 .206 .728 .853
Yes (amount unknown) 2 (2.3) 4 (2.3) 1 (2.0) 1 (1.0) 0 2 (1.2)
Social (occasional) 7 (8.1) 6 (3.5) 3 (6.0) 2 (2.0) 6 (7.4) 13 (8.0)
Heavy (daily) 1 (1.2) 1 (0.6) 0 0 0 0
No 76 (86.1) 161 (93.6) 46 (92.0) 97 (97.0) 75 (92.6) 147 (90.7)
Medical characteristics
Bleeding during pregnancy
after 12 wk
.101 .784 .360 .193 .065 .543
Yes 12 (14.0) 13 (7.6) 2 (4.0) 5 (5.0) 7 (8.6) 9 (5.6)
No 74 (86.0) 159 (92.4) 48 (96.0) 95 (95.0) 74 (91.4) 153 (94.4)
Comparisons of clinical data between cases and controls were performed using chi-square test or Fisher exact test or Mann-Whitney test, as appropriate (SAS System 9.4).
Missing values are excluded in the frequency tables.
N, number of subjects; sPTD, spontaneous preterm delivery.
Saade et al. Validation of a preterm delivery predictor. Am J Obstet Gynecol 2016.
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SUPPLEMENTARY TABLE 2
Clinical and demographic data by PAPR trial site (enrolled PAPR n[ 5501)
Variables
Site #01
n (%)
(n ¼ 385)
Site #02
n (%)
(n ¼ 684)
Site #03
n (%)
(n¼ 851)
Site #04
n (%)
(n ¼ 395)
Site #05
n (%)
(n ¼ 634)
Site #06
n (%)
(n ¼ 468)
Site #07
n (%)
(n ¼ 389)
Site #08
n (%)
(n ¼ 960)
Site #09
n (%)
(n ¼ 268)
Site #10
n (%)
(n ¼ 256)
Site #11
n (%)
(n ¼ 198)
Maternal age at
enrollment, y
18e22 y 44 (11.4) 120 (17.5) 212 (24.9) 107 (27.1) 214 (33.7) 124 (26.5) 23 (5.9) 271 (28.2) 22 (8.2) 53 (20.7) 51 (25.8)
23e27 y 147 (38.2) 152 (22.2) 261 (30.7) 107 (27.1) 189 (29.8) 150 (32.1) 69 (17.7) 272 (28.3) 66 (24.6) 65 (25.4) 64 (32.3)
28e32 y 132 (34.2) 228 (33.3) 219 (25.7) 97 (24.6) 117 (18.5) 99 (21.2) 140 (36.0) 235 (24.5) 90 (33.6) 60 (23.4) 56 (28.3)
33e37 y 50 (13.0) 145 (21.2) 111 (10.0) 57 (14.4) 81 (12.8) 71 (15.2) 105 (27.0) 127 (13.2) 64 (23.9) 56 (21.9) 24 (12.1)
38 y or more 12 (3.1) 39 (5.7) 48 (5.6) 27 (6.8) 33 (5.2) 24 (5.1) 52 (13.4) 55 (5.7) 26 (9.7) 22 (8.6) 3 (1.5)
Ethnicity
Hispanic or Latino 53 (13.8) 17 (2.8) 348 (40.9) 329 (83.3) 325 (51.3) 11 (2.4) 58 (14.9) 629 (65.5) 92 (34.3) 9 (3.5) 31 (15.6)
Non-Hispanic or Latino 332 (86.2) 665 (97.2) 503 (59.1) 66 (16.7) 309 (48.7) 457 (97.6) 331 (85.1) 331 (34.5) 176 (65.7) 247 (96.5) 167 (84.3)
Race
American
Indian/Alaskan
Native
5 (1.3) 3 (0.4) 3 (0.4) 4 (1.0) 4 (0.6) 0 5 (1.3) 3 (0.3) 1 (0.4) 4 (1.6) 1 (0.5)
Asian 6 (1.6) 10 (1.5) 25 (2.9) 15 (3.8) 10 (1.6) 5 (1.1) 23 (5.9) 13 (1.4) 33 (12.3) 0 2 (1.0)
Black or
African-American
0 285 (41.7) 245 (28.8) 19 (4.8) 128 (20.2) 242 (51.7) 11 (2.8) 104 (10.8) 20 (7.5) 35 (13.7) 65 (32.8)
Native Hawaiian
or other
Pacific Islander
6 (1.6) 2 (0.3) 0 0 1 (0.2) 0 3 (0.8) 1 (0.1) 0 1 (0.4) 0
White 349 (90.6) 371 (54.2) 570 (66.9) 353 (89.4) 335 (52.8) 204 (43.6) 339 (87.2) 837 (87.2) 205 (76.5) 213 (83.2) 110 (55.6)
Other 19 (4.9) 13 (1.9) 8 (0.9) 4 (1.0) 156 (24.6) 17 (3.6) 8 (2.0) 2 (0.2) 9 (3.4) 3 (1.2) 20 (10.1)
Number of prior sPTDs
1 or more 39 (14.8) 117 (24.5) 71 (11.5) 54 (16.4) 98 (21.0) 120 (33.3) 36 (13.2) 103 (13.9) 35 (18.0) 42 (22.2) 23 (18.9)
None 224 (85.2) 360 (75.5) 547 (88.5) 275 (83.6) 369 (79.0) 240 (66.7) 236 (86.8) 638 (86.1) 160 (82.0) 147 (77.8) 99 (81.1)
N, number of subjects; sPTD, spontaneous preterm delivery.
Saade et al. Validation of a preterm delivery predictor. Am J Obstet Gynecol 2016.
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SUPPLEMENTARY TABLE 3
Forty-four proteins meeting analytical filters that were up- or
down-regulated in sPTD vs term controls
Uniprot ID Short name Protein name
A2GL_HUMAN LRG1 Leucine-rich alpha-2-glycoprotein
AFAM_HUMAN AFM Afamin
ANGT_HUMAN AGT Angiotensinogen
APOC3_HUMAN APOC3 Apolipoprotein C-III
APOH_HUMAN APOH Beta-2-glycoprotein 1
B2MG_HUMAN B2M Beta-2-microglobulin
BGH3_HUMAN TGFBI Transforming growth factor-beta-induced protein
ig-h3
CATD_HUMAN CTSD Cathepsin D
CBPN_HUMAN CPN1 Carboxypeptidase N catalytic chain
CD14_HUMAN CD14 Monocyte differentiation antigen CD14
CFAB_HUMAN CFB Complement factor B
CHL1_HUMAN CHL1 Neural cell adhesion molecule L1-like protein
CO5_HUMAN C5 Complement C5
CO6_HUMAN C6 Complement component C6
CO8A_HUMAN C8A Complement component C8 alpha chain
CRIS3_HUMAN CRISP3 Cysteine-rich secretory protein 3
ENPP2_HUMAN ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase
family member 2
F13B_HUMAN F13B Coagulation factor XIII B chain
FBLN3_HUMAN EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1
FETUA_HUMAN AHSG Alpha-2-HS-glycoprotein
HABP2_HUMAN HABP2 Hyaluronan-binding protein 2
HEMO_HUMAN HPX Hemopexin
HLAG_HUMAN HLA-Ga HLA class I histocompatibility antigen, alpha chain G
IBP2_HUMAN IGFBP2 Insulin-like growth factor-binding protein 2
IBP3_HUMAN IGFBP3 Insulin-like growth factor-binding protein 3
IBP4_HUMAN IGFBP4 Insulin-like growth factor-binding protein 4
INHBC_HUMAN INHBC Inhibin beta C chain
ITIH3_HUMAN ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3
ITIH4_HUMAN ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 N-term
ITIH4_HUMAN ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 C-term
KNG1_HUMAN KNG1 Kininogen-1
LBP_HUMAN LBP Lipopolysaccharide-binding protein
LYAM3_HUMAN SELP P-selectin
PAPP1_HUMAN PAPPA Pappalysin-1
PEDF_HUMAN SERPINF1 Pigment epitheliumederived factor
PGRP2_HUMAN PGLYRP2 N-acetylmuramoyl-L-alanine amidase
Saade et al. Validation of a preterm delivery predictor. Am J Obstet Gynecol 2016. (continued)
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SUPPLEMENTARY TABLE 3
Forty-four proteins meeting analytical filters that were up- or
down-regulated in sPTD vs term controls (continued)
Uniprot ID Short name Protein name
PRG2_HUMAN PRG2 Bone marrow proteoglycan
PSG11_HUMAN PSG11 Pregnancy-specific beta-1-glycoprotein 11
PSG2_HUMAN PSG2 Pregnancy-specific beta-1-glycoprotein 2
PSG9_HUMAN PSG9 Pregnancy-specific beta-1-glycoprotein 9
SHBG_HUMAN SHBG Sex hormoneebinding globulin
TENX_HUMAN TNXB Tenascin-X
TIE1_HUMAN TIE1 Tyrosine-protein kinase receptor Tie-1
VTNC_HUMAN VTN Vitronectin
a Peptide surrogate for HLA-G was not unique to this protein.
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SUPPLEMENTARY TABLE 4
Performance of the ln(IBP4/SHBG) classifier by study and BMI restriction
Discovery Verification Validation
Sample # (17e28 wk)a 86, 172 50, 100 81, 162
Sample # (all BMI)a 22, 44b 9, 18b 18, 36c
AUC (all BMI) (95% CI) 0.74 (0.59e0.87) 0.77 (0.56e0.94)b 0.67 (0.52e0.81)
Sample # (BMI <35)a 17, 33b 6, 17b 15, 29c
AUC (BMI <35) (95% CI) 0.79 (0.65e0.92)b 0.79 (0.58e0.95)b 0.70 (0.53e0.86)c
95% CI calculated based on 5000 bootstrap iterations.
AUC, area under the curve; BMI, body mass index; CI, confidence interval.
a Number of cases, number of controls; b Gestational age at blood draw weeks 190/7 - 216/7; c Optimal gestational age at blood
draw interval from fixed sequence validation (191/7 - 206/7).
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SUPPLEMENTARY TABLE 5
Performance of the ln(IBP4/SHBG) classifier with different BMI restrictions
BMI (kg/m2) AUROC (95% CI) Cases Controls
All BMI 0.67 (0.52e0.82) 18 36
BMI 45 0.67 (0.52e0.82) 18 35
BMI 40 0.68 (0.52e0.83) 17 34
BMI 37 0.71 (0.53e0.86) 16 31
BMI >18 0.67 (0.52e0.82) 18 35
BMI >20 0.65 (0.51e0.82) 17 32
BMI >22 0.69 (0.53e0.86) 14 27
22 < BMI  37 0.75 (0.56e0.91) 12 23
95% CI calculated based on 5000 bootstrap iterations.
Gestational age at blood draw 191/7 - 206/7 weeks.
AUROC, area under the receiver operating characteristic curve; BMI, body mass index; CI, confidence interval.
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SUPPLEMENTARY FIGURE 1
Filtering of candidate proteins prior to predictor discovery
Shown is the starting number of proteins in the discovery dataset. Candidate proteins were reduced
by analytic criteria that included presence of SIS peptide, lack of targeting by MARS-14 depletion
column, good detectability, precision, lack of processing order effects, good preanalytical stability,
lack of effect of serum storage age, and evidence of regulation. Forty-four proteins that were either
up- or down-regulated in overlapping 3-week GA intervals remained for predictor development.
Interbatch coefficients of variability—calculated using pHGS specimens across multiple batches,
processing days, and instrumentation—are reported for the predictor proteins IBP4 and SHBG using
the discovery assay.
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SUPPLEMENTARY FIGURE 2
Reversal predictive performance across gestation
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Shown is the ROC predictive performance (AUROC) of reversals formed from the ratio of up-regulated
proteins over down-regulated proteins using samples in overlapping 3-week intervals across GABD.
Predictor performance was both analyte and GABD dependent, with spikes in performance occurring
in relatively narrow GABD ranges. Examples are given for specific reversals that demonstrated the
phenotypic properties observed (eg, waves of performance that were high early in gestation, late in
gestation, or of consistent but moderate level).
APOH, beta-2-glycoprotein 1; ITIH4, inter-alpha-trypsin inhibitor heavy chain family, member 4; BGH3, transforming growth factor-beta-
induced protein ig-h3; PSG2, pregnancy-specific beta-1-glycoprotein 2.
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SUPPLEMENTARY FIGURE 3
Histogram of IBP4/SHBG predictive performance
Shown is the frequency of AUROC values obtained by application of a bootstrapping procedure to the
combined discovery and verification datasets. The total number of samples selected with replace-
ment in each of the 2000 bootstrap iterations was equivalent to the number of samples in the
combined sample set. The mean AUROC value, shown in red, was 0.76, with 95% confidence
intervals shown in blue.
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